Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000818890 | SCV000959527 | likely benign | Charcot-Marie-Tooth disease type 2 | 2024-05-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004028994 | SCV002756177 | uncertain significance | not specified | 2022-05-03 | criteria provided, single submitter | clinical testing | The p.H641Y variant (also known as c.1921C>T), located in coding exon 16 of the GARS gene, results from a C to T substitution at nucleotide position 1921. The histidine at codon 641 is replaced by tyrosine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the supporting evidence, this variant is unlikely to be causative of GARS-associated axonal neuropathy (AD); however, its contribution to the development of cytoplasmic and mitochondrial glycine-tRNA ligase deficiency (AR) is uncertain. |
Gene |
RCV004702453 | SCV005201344 | uncertain significance | not provided | 2023-09-14 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function |